Toggle navigation
Home
Search
Services
Blog
Contact
About
Vaccinotherapy for Recurrent Herpes Simplex Keratitis
Neumann, Ron
Massachusetts Eye and Ear Infirmary, Boston, MA, United States
Search grants from Ron Neumann
Search grants from Massachusetts Eye and Ear Infirmary
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Mechanisms of Resveratrol Induced Neuroprotection
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)
Methodology issues in a tailored light treatment for persons with dementia
Function of Hnrna Binding Proteins
Grants for Geriatric Education Centers
Recently added grants:
Mechanism-based drug repurposing and novel treatments for glioblastoma
Targeting lymph node metastases to prevent cancer progression
Smart and self-reporting clinical nano carriers for drug delivery
The Role of 27-hydroxycholesterol in Breast Cancer: A Population-Based Multiethnic Study
Development of a microfluidic primary cell editing platform (pCEP) for personal gene therapy
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Fogarty International Center (FIC)
Type
International Research Fellowships (FIC) (F05)
Project #
1F05TW004420-01
Application #
3022015
Study Section
International and Cooperative Projects 1 Study Section (ICP)
Project Start
1990-09-30
Project End
Budget Start
1990-09-28
Budget End
1991-09-27
Support Year
1
Fiscal Year
1990
Total Cost
Indirect Cost
Institution
Name
Massachusetts Eye and Ear Infirmary
Department
Type
DUNS #
073825945
City
Boston
State
MA
Country
United States
Zip Code
02114
Related projects
NIH 1991
F05 TW
Vaccinotherapy for Recurrent Herpes Simplex Keratitis
Neumann, Ron / Massachusetts Eye and Ear Infirmary
NIH 1990
F05 TW
Vaccinotherapy for Recurrent Herpes Simplex Keratitis
Neumann, Ron / Massachusetts Eye and Ear Infirmary
Comments
Be the first to comment on Ron Neumann's grant